Opdam, Frans L.

Lapatinib for Advanced or Metastatic Breast Cancer

Opdam, F. L., Guchelaar, H.-J., Beijnen, J. H., & Schellens, J. H. M. (2012) · The Oncologist

HER2/EGFR in Cancer ResearchCancer Treatment and Pharmacology

Cited by 113

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

van Geel, R. M. J. M., van Brummelen, E. M. J., Eskens, F. A. L. M., Huijberts, S. C. F. A., de Vos, F. Y. F. L., Lolkema, M. P. J. K., Devriese, L. A., Opdam, F. L., Marchetti, S., Steeghs, N., et al. (2020) · British Journal of Cancer

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 55

Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib ± binimetinib or alpelisib

Huijberts, S. C. F. A., Boelens, M. C., Bernards, R., & Opdam, F. L. (2021) · British Journal of Cancer

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 36

Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer

Brummelen, E. M. J., Huijberts, S., Herpen, C., Desar, I., Opdam, F., Geel, R., Marchetti, S., Steeghs, N., Monkhorst, K., Thijssen, B., et al. (2021) · The Oncologist

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 32